Fmr LLC Decreases Stock Holdings in Invivyd, Inc. (NASDAQ:IVVD)

FMR LLC lessened its holdings in shares of Invivyd, Inc. (NASDAQ:IVVD - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,320,982 shares of the company's stock after selling 1,046,775 shares during the quarter. FMR LLC owned about 6.13% of Invivyd worth $7,467,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in IVVD. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after purchasing an additional 31,992 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after buying an additional 474,301 shares in the last quarter. Duquesne Family Office LLC purchased a new position in Invivyd during the 2nd quarter valued at approximately $629,000. Renaissance Technologies LLC purchased a new stake in shares of Invivyd during the 2nd quarter worth approximately $421,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Invivyd during the 2nd quarter valued at approximately $263,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Invivyd

In related news, Director Terrance Mcguire sold 150,000 shares of the business's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the transaction, the director now owns 4,538,079 shares of the company's stock, valued at $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 17.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IVVD has been the subject of a number of recent research reports. Morgan Stanley dropped their price objective on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. HC Wainwright decreased their price objective on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, November 20th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research note on Thursday, November 21st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $7.89.

Invivyd Stock Performance

Shares of Invivyd stock traded down $0.03 on Friday, hitting $0.55. 732,593 shares of the company traded hands, compared to its average volume of 649,152. Invivyd, Inc. has a 52 week low of $0.54 and a 52 week high of $5.20. The stock's 50 day moving average price is $0.84 and its 200-day moving average price is $1.08.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.